Relay Therapeutics (RLAY) Cash from Financing Activities (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Cash from Financing Activities of $138.8 million for Q1 2026, up 14758.89% quarter-over-quarter from $934000.0 in Q4 2025.
Relay Therapeutics (RLAY) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Cash from Financing Activities for 8 consecutive years, with $138.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $138.8 million; the TTM figure through Mar 2026 stood at $140.5 million (changed N/A YoY), while the FY2025 annual figure was $1.6 million, down 99.41% from the prior year.
- Cash from Financing Activities rose to $138.8 million in Q1 2026 per RLAY's latest filing, from $934000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $285.9 million in Q3 2022 and bottomed at $17000.0 in Q3 2025.
- Historically, Cash from Financing Activities has averaged $49.0 million across 5 years, with a median of $2.0 million in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 31592.35% — and 2025, when it sank 99.99%.
- Relay Therapeutics' Cash from Financing Activities stood at $1.2 million in 2022, then jumped by 1779.76% to $21.9 million in 2023, then tumbled by 96.35% to $800000.0 in 2024, then gained by 16.75% to $934000.0 in 2025, then soared by 14758.89% to $138.8 million in 2026.
- Business Quant data shows RLAY's Cash from Financing Activities at $138.8 million in Q1 2026, $934000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 323.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 323.74 Mn |
| Jun 30, 2026 | 323.74 Mn |
| Mar 31, 2026 | 138.78 Mn |
| Mar 31, 2026 | 138.78 Mn |
| Dec 31, 2025 | 934,000.00 |
| Dec 31, 2025 | 934,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 218.89 Mn |
| Sep 30, 2024 | 218.89 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 48.92 Mn |
| Mar 31, 2024 | 48.92 Mn |
| Dec 31, 2023 | 21.92 Mn |
| Dec 31, 2023 | 21.92 Mn |
| Sep 30, 2023 | 9.46 Mn |
| Sep 30, 2023 | 9.46 Mn |